Slide 1: Ipsen Q3 2018 Sales
Ipsen Q3 2018 Sales October 25, 2018
Slide 2: Disclaimer & Safe Harbor
Disclaimer & Safe Harbor This presentation includes only summary information and does not purport to be comprehensive. Forward-looking statements, targets and estimates contained herein are for illustrative purposes only and are based on management’s current views and assumptions. Such statements in
Slide 3: Q3 2018 financial highlights
Q3 2018 financial highlights ▪ Solid third quarter with Group sales growth of +20.2%(1) driven by Specialty Care +24.2%(1) and Consumer Healthcare +5.0%(1) ▪ YTD Group strong sales growth of +21.1% (1) ▪ Specialty Care sales growth of +25.8%(1) driven by Somatuline® and Dysport® momentum and contrib
Slide 4: Oncology: Driving Specialty Care franchise at +30.9% growth YTD
Oncology: Driving Specialty Care franchise at +30.9% (1) growth YTD Commercial highlights Pipeline highlights Somatuline® Recent achievements: ▪ Strong global momentum and market share gains with ▪ Cabometyx®: Positive CHMP opinion for 2L HCC 39%(1) sales growth in North America, 13%(1) in Europe ▪
Slide 5: Neuroscience: Dysport strong growth momentum of +15.4% YTD
Neuroscience: Dysport ® strong growth momentum of +15.4% (1) YTD Therapeutics Aesthetics ▪ Strong momentum in the U.S. with new ▪ Continued excellent market performance by indications and commercial partnership partner Galderma ▪ Strong growth in Ipsen-led aesthetics ▪ Strong performance in Rest of
Slide 6: Priorities to deliver 2018 objectives
Priorities to deliver 2018 objectives Growth story ▪ Support growth and market share gains worldwide for differentiated best- in-class established Specialty Care products Top ▪ Maximize market penetration for Cabometyx® and Onivyde® through line strong clinical data and unique mechanisms of action ▪
Slide 7: Q&A
Q&A David Meek, CEO Aymeric Le Chatelier, CFO 7
Slide 8: YTD 2018 sales growth driven by Specialty Care
YTD 2018 sales growth driven by Specialty Care Net sales YTD 2018 in million euros – % excluding foreign exchange impact Group Sales €1,620.4m Somatuline® 620 +26% +21.1% Specialty Care Decapeptyl® 273 +7% Cabometyx® 101 Specialty Care Onivyde® €1,404.2m 76 +25.8% Dysport® 261 +15% Nutropin® 35 -10%
Slide 9: Q3 2018 sales growth driven by Specialty Care
Q3 2018 sales growth driven by Specialty Care Net sales Q3 2018 in million euros – % excluding foreign exchange impact Group Sales €555.9m Somatuline® 217 +26% +20.2% Specialty Care Decapeptyl® 89 +2% Cabometyx® 39 Specialty Care Onivyde® €484.1m 27 +24.2% Dysport® 88 +21% Nutropin® 11 -9% Increlex®